Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.36 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.36 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKLR | P30613 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21004687 | 0.99 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL25771124 | 0.94 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL21004644 | 0.82 | ALDH1A1 (0.46) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL21151389 | 0.80 | LMNA (0.45) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL21783598 | 0.79 | ALDH1A1 (0.37) | LMNAALDH1A1HTT | |
| SCHEMBL17100765 | 0.78 | MAPT (0.58) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL21834072 | 0.77 | PKM (0.53) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL25245611 | 0.76 | ALDH1A1 (0.46) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL28958551 | 0.76 | LMNA (0.47) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6886969 | 0.75 | USP2 (0.65) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113226356-B | Activation of pyruvate kinase R | 诺沃挪第克健康护理股份公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240391922-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Novo Nordisk Heathcare AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12122778-B2 | Activating pyruvate kinase R | NOVO NORDISK HEALTH CARE AG (CH) | 2024-10-22 | — | — | US | disclosed |
| US-12071440-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | NOVO NORDISK HEALTH CARE AG (CH) | 2024-08-27 | — | — | US | disclosed |
| EP-3852791-B1 | ACTIVATING PYRUVATE KINASE R | NOVO NORDISK HEALTHCARE AG (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240083901-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | NOVO NORDISK HEALTH CARE AG (CH) | 2024-03-14 | — | — | US | disclosed |
| CN-115304605-B | Oxetane derivatives with antitumor activity, and preparation method and application thereof | 陕西国际商贸学院 | 2023-10-03 | — | — | CN | disclosed |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | FORMA THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230055923-A1 | ACTIVATING PYRUVATE KINASE R | NOVO NORDISK HEALTH CARE AG (CH) | 2023-02-23 | — | — | US | disclosed |
| CN-115304605-A | Oxetane derivative with anti-tumor activity and preparation method and application thereof | 陕西国际商贸学院 | 2022-11-08 | — | — | CN | disclosed |
| US-11014927-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | FORMA THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11001588-B2 | Activating pyruvate kinase R and mutants thereof | FORMA THERAPEUTICS, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3680241-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Forma Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2020061255-A1 | ACTIVATING PYRUVATE KINASE R | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20200087309-A1 | ACTIVATING PYRUVATE KINASE R AND MUTANTS THEREOF | NOVO NORDISK HEALTH CARE AG, (CH) | 2020-03-19 | — | — | US | disclosed |
| US-20200069643-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | NOVO NORDISK HEALTH CARE AG, (CH) | 2020-03-05 | — | — | US | disclosed |
| EP-3483164-B1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | FORMA THERAPEUTICS INC (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3448859-B1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | FORMA THERAPEUTICS INC (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3483164-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Forma Therapeutics, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018175474-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | FORMA THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055923-A1 | ACTIVATING PYRUVATE KINASE R | PDK1, PDK2, PKLR | HTR6 4421/4885DRD1 4504/4885HSP90AA1 829/4885 |
| US-20200069643-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | PDK1, PKM, PKLR | HTR6 4609/4885DRD1 3745/4885HSP90AA1 1418/4885 |
| US-20240391922-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | PDK1, PKM, PKLR | HTR6 4529/4885DRD1 2935/4885HSP90AA1 1242/4885 |
| US-11014927-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | PDK1, PKM, PKLR | HTR6 4609/4885DRD1 3745/4885HSP90AA1 1418/4885 |
| US-12071440-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | PDK1, PKM, PKLR | HTR6 4529/4885DRD1 2935/4885HSP90AA1 1242/4885 |
| US-20240083901-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | PDK1, PKM, PKLR | HTR6 4529/4885DRD1 2935/4885HSP90AA1 1242/4885 |
| US-11001588-B2 | Activating pyruvate kinase R and mutants thereof | PDK1, PKLR, PDK2 | HTR6 4323/4885DRD1 4507/4885HSP90AA1 967/4885 |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | PDK1, PKM, PKLR | HTR6 4529/4885DRD1 2935/4885HSP90AA1 1242/4885 |
| US-20200087309-A1 | ACTIVATING PYRUVATE KINASE R AND MUTANTS THEREOF | PDK1, PKLR, PDK2 | HTR6 4323/4885DRD1 4507/4885HSP90AA1 967/4885 |
| US-12122778-B2 | Activating pyruvate kinase R | PDK1, PDK2, PKLR | HTR6 4421/4885DRD1 4504/4885HSP90AA1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.